Bladder Cancer

Patients with non-muscle invasive bladder cancer who smoke should consider quitting to possibly improve health outcomes in survivorship, according to an expert.

Sexual dysfunction is not less common in women with bladder cancer who undergo reproductive organ-sparing radical cystectomy, although more research is needed.

Men often decide to tough out their cancer alone, but tough guy Terry Bradshaw is starting to open up about his sometimes-rocky journey with the disease.

From a childhood cancer survivor throwing out the first pitch at Game 4 of the World Series to former WWE champion and actor Dwayne “The Rock” Johnson recording a message for a child with brain cancer, here’s what’s happening in the cancer space this week.

Talking about the end of life can be difficult, but these conversations are crucial for patients with incurable cancer to have with their clinicians, experts say.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about support available for patients and caregivers following a bladder cancer diagnosis.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about the role of the caregiver in bladder cancer and how they can also seek support to aid them.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about letting physicians know about patient preferences to improve communication and select the right treatment option.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.

Long-term outcomes from this trial confirm the benefit of treatment with chemoradiotherapy over chemotherapy alone for patients with muscle-invasive bladder cancer.

The phase 3 MAGNOLIA trial will assess whether abelacimab can prevent venous thromboembolism recurrence in patients with gastrointestinal or genitourinary cancers.

More than half of patients with metastatic, cisplatin-ineligible bladder cancer saw their cancer shrink when given Padcev and Keytruda in a clinical trial.

The FDA granted abelacimab a fast track designation for the treatment of thrombosis, a common and sometimes deadly type of blood clot associated with cancer.

Backed by her personal cancer experience, an oncology nurse became a volunteer with the Bladder Cancer Advocacy Network.

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer.

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

The clinical development of BEMPEG plus Opdivo will end after clinical trials showed that the drug combination did not lead to significant improvements in outcomes in patients with kidney or bladder cancer.

Investigators plan to enroll approximately 90 patients with squamous cell carcinoma of the head and neck, as well as metastatic bladder and non-small cell lung cancer.

Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.